__timestamp | Mesoblast Limited | Supernus Pharmaceuticals, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 25434000 | 5758000 |
Thursday, January 1, 2015 | 23783000 | 8423000 |
Friday, January 1, 2016 | 29763000 | 11986000 |
Sunday, January 1, 2017 | 12065000 | 15215000 |
Monday, January 1, 2018 | 5508000 | 15356000 |
Tuesday, January 1, 2019 | 75173000 | 16660000 |
Wednesday, January 1, 2020 | 81497000 | 52459000 |
Friday, January 1, 2021 | 85731000 | 75061000 |
Saturday, January 1, 2022 | 63572000 | 87221000 |
Sunday, January 1, 2023 | 54922000 | 83779000 |
Monday, January 1, 2024 | 41070000 |
Unleashing insights
In the ever-evolving landscape of pharmaceuticals, understanding cost dynamics is crucial. Supernus Pharmaceuticals, Inc. and Mesoblast Limited, two prominent players, have shown intriguing trends in their cost of revenue over the past decade. From 2014 to 2023, Mesoblast Limited's expenses surged by approximately 60%, peaking in 2021. Meanwhile, Supernus Pharmaceuticals experienced a staggering 1,400% increase, reaching its zenith in 2022. This dramatic rise highlights the challenges and investments required in the pharmaceutical industry. Notably, 2023 saw a slight decline for both companies, indicating potential shifts in strategy or market conditions. Missing data for 2024 suggests ongoing developments. These insights not only reflect the financial health of these companies but also underscore the broader economic pressures faced by the sector. As the industry continues to innovate, keeping an eye on such financial metrics will be essential for stakeholders.
AbbVie Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Pfizer Inc. and Supernus Pharmaceuticals, Inc.
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Mesoblast Limited
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Mesoblast Limited's Expenses
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Mesoblast Limited's Expenses
Cost of Revenue Comparison: Alkermes plc vs Mesoblast Limited
Analyzing Cost of Revenue: Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Bausch Health Companies Inc. vs Mesoblast Limited
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Selling, General, and Administrative Costs: Supernus Pharmaceuticals, Inc. vs Mesoblast Limited
Mesoblast Limited vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored